ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr

Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market

Divestment, privatisation, stake sale, disinvestment
Its revenue rose to Rs 720 crore for the first quarter of 2024-25 from Rs 467 crore in the year-ago period.
Press Trust of India New Delhi
2 min read Last Updated : Aug 22 2024 | 8:50 PM IST

Private equity major ChrysCapital on Thursday exited Eris Lifesciences by selling its entire 7.27 per cent stake in the company for Rs 1,187 crore via open market transaction, while Infinity Partners picked up shares of the firm.

Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market.

According to the block deal data available on the National Stock Exchange (NSE), ChrysCapital through its affiliate Emerald Investment Ltd sold 98,86,882 shares, amounting to a 7.27 per cent stake in Ahmedabad-based Eris Lifesciences.

The shares were disposed of at an average price of Rs 1,201 apiece, taking the transaction value to Rs 1,187.41 crore.

These shares were picked up by Infinity Partners at the same price, as per the data on the exchange.

Shares of Eris Lifesciences rose 2.13 per cent to close at Rs 1,238.65 apiece on the NSE.

Earlier this month, Eris Lifesciences said its consolidated profit after tax declined by 4.5 per cent year-on-year to Rs 89 crore for the quarter ended on June 30, 2024.

The drug maker reported a profit after tax of Rs 94 crore in the April-June quarter of the last fiscal.

Its revenue rose to Rs 720 crore for the first quarter of 2024-25 from Rs 467 crore in the year-ago period.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Private EquityStock MarketEris Lifesciences

First Published: Aug 22 2024 | 8:50 PM IST

Next Story